C1 inhibitor: Biologic activities that are independent of protease inhibition

Immunobiology

Volumn 212, Issue 4-5, 2007, Pages 313-323

  Davis III, Alvin E ^a   Cai, Shenghe ^a   Liu, Dongxu ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

C1 inhibitor; Cecal ligation and puncture model; Endotoxin shock; Gram negative bacterial sepsis; Selectins; Serine proteinase inhibitors

Indexed keywords

COLLAGEN TYPE 4; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTOXIN; ENTACTIN; FIBRINOGEN; LAMININ; PADGEM PROTEIN; PROTEINASE; SIALYL LEWIS X ANTIGEN;

ACUTE GRAFT REJECTION; ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; CELL INTERACTION; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; ENDOTHELIUM CELL; ENZYME INHIBITION; GRAM NEGATIVE INFECTION; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATORY DISEASE; LEUKOCYTE MIGRATION; MACROPHAGE; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REPERFUSION INJURY; REVIEW; SEPSIS; SEPTIC SHOCK; SINGLE DRUG DOSE; VASCULAR DISEASE;

EID: 34249749471     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2006.10.003     Document Type: Review

References (94)

1. Aderem A., and Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature 406 (2000) 782-787
2. Akita N., Nakase H., Kaido T., Kanemoto Y., and Sakaki T. Protective effect of C1 esterase inhibitor on reperfusion injury in the rat middle cerebral artery occlusion model. Neurosurgery 52 (2003) 395-400
3. Ambrus G., Gal P., Kojima M., Szilagyi K., Balczer J., Antal J., Graf L., Laich A., Moffatt B.E., Schwaeble W., Sim R.B., and Zavodszky P. Natural substrates and inhibitors of mannan-binding lectin-associated serine protease-1 and -2: a study on recombinant catalytic fragments. J. Immunol. 170 (2003) 1374-1382
4. Barton P.A., and Warren J.S. Complement component C5 modulates the systemic tumor necrosis factor response in murine endotoxic shock. Infect. Immun. 61 (1993) 1474-1481
5. Bauernschmitt R., Bohrer H., and Hagl S. Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA. Intensive Care Med. 24 (1998) 635-638
6. Bauernschmitt R., Schreiber C., and Lange R. C1 esterase inhibitor concentrate during surgery with cardiopulmonary bypass: is there an indication beyond substitution therapy in patients with hereditary angioneurotic edema?. J. Thorac. Cardiovasc. Surg. 120 (2000) 427-428
7. Bergamaschini L., Gatti S., Caccamo L., Prato P., Latham L., Trezza P., Maggioni M., Gobbo G., and Fassati L.R. C1 inhibitor potentiates the protective effect of organ preservation solution on endothelial cells during cold storage. Transplant. Proc. 33 (2001) 939-941
8. Bergamaschini L., Gobbo G., Gatti S., Caccamo L., Prato P., Maggioni M., Braidotti P., Di Stefano R., and Fassati L.R. Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver. Clin. Exp. Immunol. 126 (2001) 412-420
9. Brinkman-van der Linden E.C., de Haan P.F., Havenaar E.C., and van Dijk W. Inflammation-induced expression of sialyl Lewisx is not restricted to alpha1-antichymotrypsin and haptoglobin. Glycoconj. J. 15 (1998) 177-182
10. Buerke M., Murohara T., and Lefer A.M. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 91 (1995) 393-402
11. Buerke M., Prufer D., Dahm M., Oelert H., Meyer J., and Darius H. Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury. J. Pharmacol. Exp. Ther. 286 (1998) 429-438
12. Butcher E.C., and Picker L.J. Lymphocyte homing and homeostasis. Science 272 (1996) 60-66
13. Cai S., and Davis III A.E. Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion. J. Immunol. 171 (2003) 4786-4791
14. Cai S., Dole V., Bergmeier W., Scafidi J., Feng H., Wagner D.D., and Davis III A.E. A direct role for C1 inhibitor in leukocyte adhesion. J. Immunol. 174 (2005) 6462-6466
15. Colman R.W. Biologic activities of the contact factors in vivo. Potentiation of hypotension, inflammation, and fibrinolysis, and inhibition of cell adhesion, angiogenesis and thrombosis. Thromb. Haemost. 82 (1999) 1568-1577
16. Czermak B.J., Sarma V., Pierson C.L., Warner R.L., Huber-Lang M., Bless N.M., Schmal H., Priedl H.P., and Ward P.A. Protective effects of C5a blockage in sepsis. Nat. Med. 5 (1999) 788-792
17. Dalmasso A.P., and Platt J.L. Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor. Transplantation 56 (1993) 1171-1176
18. da Silva Correia J., and Ulevitch R.J. MD-2 and TLR4 N-linked glycoproteins are important for a functional lipopolysaccharide receptor. J. Biol. Chem. 277 (2002) 1845-1854
19. de Agostini A., Lijnen H.R., Pixley R.A., Colman R.W., and Schapira M. Inactivation of factor-XII active fragment in normal plasma: predominant role of C1-inhibitor. J. Clin. Invest. 93 (1984) 1542-1549
20. De Graaf T.W., Van der Stelt M.E., Anbergen M.G., and van Dijk W. Inflammation-induced expression of sialyl Lewis X-containing glycan structures on alpha 1-acid glycoprotein orosomucoid in human sera. J. Exp. Med. 177 (1993) 657-666
21. De Simoni M.G., Storini C., Barba M., Catapano L., Arabia A.M., Rossi E., and Bergamaschini L. Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemia. J. Cereb. Blood Flow Metab. 23 (2003) 232-239
22. De Simoni M.G., Rossi E., Storini C., Pizzimenti S., Echart C., and Bergamaschini L. The powerful neuroprotective action of C1-inhibitor on brain ischemia-reperfusion injury does not require C1q. Am. J. Pathol. 164 (2004) 1857-1863
23. De Simoni M.G., Rossi E., Storini C., Pizzimenti S., Echart C., and Bergamaschini L. The powerful neuroprotective action of C1-inhibitor on brain ischemia-reperfusion injury does not require C1q. Am. J. Pathol. 164 (2004) 1857-1863
24. de Zwaan C., Kleine A.H., Diris J.H., Glatz J.F., Wellens H.J., Strengers P.F., Tissings M., Hack C.E., van Dieijen-Visser M.P., and Hermens W.T. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur. Heart J. 23 (2002) 1670-1677
25. Feletou M., Jamonneau I., Germain M., Thurieau C., Fauchere J.L., Villa P., Ghezzi P., and Canet E. Bradykinin B2 receptor involvement in rabbit and murine models of septic shock. J. Cardiovasc. Pharmacol. 27 (1996) 500-507
26. Fenton M.J., and Golenbock D.T. LPS-binding proteins and receptors. J. Leukoc. Biol. 64 (1998) 25-32
27. Ferguson A.D., Welte W., Hofmann E., Lindner B., Holst O., Coulton J.W., and Diederichs K. A conserved structural motif for lipopolysaccharide recognition by procaryotic and eucaryotic proteins. Structure 8 (2000) 585-592
28. Fiane A.E., Videm V., Johansen H.T., Mellbye O.J., Nielsen E.W., and Mollnes T.E. C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-to-human perfusion model. Immunopharmacology 42 (1999) 231-243
29. Fischer M.B., Prodeus A.P., Nicholson-Weller A., Ma M., Murrow J., Reid R.R., Warren H.B., Lage A.L., Moore J.F.D., Rosen F.S., and Carroll M.C. Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement. J. Immunol. 159 (1997) 976-982
30. Frenette P.S., and Wagner D.D. Adhesion molecules - first of two parts. N. Engl. J. Med. 334 (1996) 1526-1529
31. Frenette P.S., and Wagner D.D. Adhesion molecules - Part II: blood vessels and blood cells. N. Engl. J. Med. 335 (1996) 43-45
32. Fukuta D., Miyagawa S., Yamada M., Matsunami K., Kurihara T., Shirasu A., Hattori H., and Shirakura R. Effect of various forms of the C1 esterase inhibitor (C1-INH) and DAF on complement mediated xenogeneic cell lysis. Xenotransplantation 10 (2003) 132-141
33. Giebler R., Schmidt U., Koch S., Peters J., and Scherer R. Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin. Crit. Care Med. 27 (1999) 597-604
34. Guerrero R., Velasco F., Rodriguez M., Lopez A., Rojas R., Alvarez M.A., Villalba R., Rubio V., Torres A., and Castillo D.d. Endotoxin-induced pulmonary dysfunction is prevented by C1-esterase inhibitor. J. Clin. Invest. 91 (1993) 2754-2760
35. Hack C.E., Ogilvie A.C., Eisele B., Eerenberg A.J., Wagstaff J., and Thijs L.G. C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med. 19 Suppl. 1 (1993) S19-S28
36. Hack C.E., Ogilvie A.C., Eisele B., Jansen P.M., Wagstaff J., and Thijs L.G. Initial studies on the administration of C1-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy. Prog. Clin. Biol. Res. 388 (1994) 335-357
37. Hattori R., Hamilton K.K., McEver R.P., and Sims P.J. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J. Biol. Chem. 264 (1989) 9053-9060
38. Hauert J., Patston P.A., and Schapira M. C1 inhibitor cross-linking by tissue transglutaminase. J. Biol. Chem. 275 (2000) 14558-14562
39. Hecker J.M., Lorenz R., Appiah R., Vangerow B., Loss M., Kunz R., Schmidtko J., Mengel M., Klempnauer J., Piepenbrock S., Dickneite G., Neidhardt H., Ruckoldt H., and Winkler M. C1-inhibitor for prophylaxis of xenograft rejection after pig to cynomolgus monkey kidney transplantation. Transplantation 73 (2002) 675-677
40. Henze U., Lennartz A., Hefemann B., Goldmann C., Kirkpatrick C.J., and Klosterhalfen B. The influence of the C1-inhibitor BERINERT and the protein-free haemodialsate ACTIHAEMYL20% on the evolution of the depth of scald burns in a porcine model. Burns 23 (1997) 473-477
41. Horstick G., Heimann A., Gotze O., Hafner G., Berg O., Bohmer P., Becker P., Darius H., Rupprecht H.J., Loos M., Bhakdi S., Meyer J., and Kempski O. Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces necrosis in an experimental model of ischemia reperfusion. Circulation 95 (1997) 701-708
42. Horstick G., Berg O., Heimann A., Gotze O., Loos M., Hafner G., Bierbach B., Petersen S., Bhakdi S., Darius H., Horstick M., Meyer J., and Kempski O. Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation 104 (2001) 3125-3131
43. Horstick G., Kempf T., Lauterbach M., Bhakdi S., Kopacz L., Heimann A., Malzahn M., Horstick M., Meyer J., and Kempski O. C1-esterase-inhibitor treatment at early reperfusion of hemorrhagic shock reduces mesentery leukocyte adhesion and rolling. Microcirculation 8 (2001) 427-433
44. Horstick B., Berg O., Heimann A., Gotze O., Loos M., Hafner G., Bierbach B., Petersen S., Bhakdi S., Darius H., Horstick M., Meyer J., and Kempski O. Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation 104 (2002) 3125-3131
45. Jagels M.A., Daffern P.J., and Hugli T.E. C3a and C5a enhance granulocyte adhesion to endothelial and epithelial cell monolayers: epithelial and endothelial priming is required for C3a-induced eosinophil adhesion. Immunopharmacology 46 (2000) 209-222
46. Jansen P.M., Pixley R.A., Brouwer M., de Jong I.W., Chang A.C., Hack C.E., Taylor Jr. F.B., and Colman R.W. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 87 (1996) 2337-2344
47. Jansen P.M., Eisele B., de Jong I.W., Chang A., Delvos U., Taylor J.F.B., and Hack C.E. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J. Immunol. 160 (1998) 475-484
48. Jiang H., Wagner E., Zhang H., and Frank M.M. Complement 1 inhibitor is a regulator of the alternative complement pathway. J. Exp. Med. 194 (2001) 1609-1616
49. Juan T.S., Hailman E., Kelley M.J., Busse L.A., Davy E., Empig C.J., Narhi L.O., Wright S.D., and Lichenstein H.S. Identification of a lipopolysaccharide binding domain in CD14 between amino acids 57 and 64. J. Biol. Chem. 270 (1995) 5219-5224
50. Kaplan A.P., Gruber A., and Harpel P.C. Assessment of Hageman factor activation in human plasma: quantification of activated Hageman factor-C1 inactivator complexes by an enzyme-linked differential antibody immunosorbent assay. Blood 66 (1985) 636-641
51. Khorram-Sefat R., Goldmann C., Radke A., Lennartz A., Mottaghy K., Afify M., Kupper W., and Klosterhalfen B. The therapeutic effect of C1-inhibitor on gut-derived bacterial translocation after thermal injury. Shock 9 (1998) 101-108
52. Kirschfink M., and Nurnberger W. C1 inhibitor in anti-inflammatory therapy: from animal experiment to clinical application. Mol. Immunol. 36 (1999) 225-232
53. Kitchens R.L. Role of CD14 in cellular recognition of bacterial lipopolysaccharides. Chem. Immunol. 74 (2000) 61-82
54. Lamping N., Hoess A., Yu B., Park T.C., Kirschning C.-J., Pfeil C., Reuter D., Wright S.D., Herrman F., and Schumann R.R. Effects of site directed mutagenesis of basic residues (Arg 94, Lys 95, Lys 99) of LPS-binding protein on binding and transfer of LPS and subsequent immune cell activation. J. Immunol. 157 (1996) 4648-4656
55. Lehmann T.G., Heger M., Munch S., Kirschfink M., and Klar E. In vivo microscopy reveals that complement inhibition by C1-esterase inhibitor reduces ischemia/reperfusion injury in the liver. Transpl. Int. 13 Suppl. 1 (2000) S547-S550
56. Lehmann C., Birnbaum J., Luhrs C., Ruckbeil O., Spies C., Ziemer S., Grundling M., Pavlovic D., Usichenko T., Wendt M., and Kox W.J. Effects of C1 esterase inhibitor administration on intestinal functional capillary density, leukocyte adherence and mesenteric plasma extravasation during experimental endotoxemia. Intensive Care Med. 30 (2004) 309-314
57. Liu D., Cai S., Gu X., Scafidi J., Wu X., and Davis III A.E. C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J. Immunol. 171 (2003) 2594-2601
58. Liu D., Gu X., Scafidi J., and Davis III A.E. N-linked glycosylation is required for C1 inhibitor-mediated protection from endotoxin shock in mice. Infect. Immun. 72 (2004) 1946-1955
59. Liu D., Cramer C.C., Scafidi J., and Davis III A.E. N-linked glycosylation at Asn3 and the positively charged residues within the amino terminal domain of C1 inhibitor are required for its interaction with Salmonella typhimurium lipopolysaccharide and lipid A. Infect. Immun. 73 (2005) 4478-4487
60. Liu D., Zhang D., Scafidi J., Wu X., Cramer C.C., and Davis III A.E. C1 inhibitor prevents Gram negative bacterial lipopolysaccharide-induced vascular permeability. Blood 72 (2005) 1946-1955
61. Mancek M., Pristovsek P., and Jerala R. Identification of LPS-binding peptide fragment of MD-2, a Toll-receptor accessory protein. Biochem. Biophys. Res. Commun. 292 (2002) 880-885
62. Matsunami K., Miyagawa S., Yamada M., Yoshitatsu M., and Shirakura R. A surface-bound form of human C1 esterase inhibitor improves xenograft rejection. Transplantation 69 (2000) 749-755
63. Matsushita M., Endo Y., and Fujita T. Cutting edge: complement-activating complex of ficolin and mannose-binding lectin-associated serine protease. J. Immunol. 164 (2000) 2281-2284
64. Matsushita M., Thiel S., Jensenius J.C., Terai I., and Fujita T. Proteolytic activities of two types of mannose-binding lectin associated serine protease. J. Immunol. 165 (2000) 2637-2642
65. Matsushita M., Endo Y., Hamasaki N., and Fujita T. Activation of the lectin complement pathway by ficolins. Int. Immunopharmacol. 1 (2001) 359-363
66. Monsinjon T., Gasque P., Chan P., Ischenko A., Brady J.J., and Fontaine M.C. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J. 17 (2003) 1003-1014
67. Niederau C., Brinsa R., Niederau M., Luthen R., Strohmeyer G., and Ferrell L.D. Effects of C1-esterase inhibitor in three models of acute pancreatitis. Int. J. Pancreatol. 17 (1995) 189-196
68. Nielsen E.W., Mollnes T.E., Harlan J.M., and Winn R.K. C1-inhibitor reduces the ischaemia-reperfusion injury of skeletal muscles in mice after aortic cross-clamping. Scand. J. Immunol. 56 (2002) 588-592
69. Ogilvie A.C., Baars J.W., Eerenberg A.J.M., Hack C.E., Pinedo H.M., Thijs L.G., and Wagstaff J. A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2. Br. J. Cancer 69 (1994) 596-598
70. Patston P.A., and Schapira M. Regulation of C1-inhibitor function by binding to type IV collagen and heparin. Biochem. Biophys. Res. Commun. 230 (1997) 597-601
71. Pixley R.A., Schapira M., and Colman R.W. The regulation of human factor XIIa by plasma proteinase inhibitors. J. Biol. Chem. 260 (1985) 1723-1729
72. Pixley R.A., De La Cadena R., Page J.D., Kaufman N., Wyshock E.G., Chang A., Taylor Jr. F.B., and Colman R.W. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J. Clin. Invest. 91 (1993) 61-68
73. Poltorak A., He X., Smirnova I., Liu M.Y., van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., and Beutler B. Defective LPS signaling in C3H/HeJ and C57Bl/10ScCr mice: mutations in the Tlr4 gene. Science 282 (1998) 2085-2088
74. Przemeck M., Lorenz R., Vangerow B., Klempnauer J., Winkler M., and Piepenbrock S. Pretreatment with C1-esterase inhibitor improves cardiovascular stability in small primates undergoing porcine kidney xenotransplantation. Transplant. Proc. 34 (2002) 2383
75. Radke A., Mottaghy K., Goldmann C., Khorram-Sefat R., Kovacs B., Janssen A., Klosterhalfen B., Hafemann B., Pallua N., and Kirschfink M. C1 inhibitor prevents capillary leakage after thermal trauma. Crit. Care Med. 28 (2000) 3224-3232
76. Schelzig H., Simon F., Krischer C., Vogel A., and Abendroth D. Ex-vivo hemoperfusion (eHPS) of pig-lungs with whole human blood: effects of complement inhibition with a soluble C1-esterase-inhibitor. Ann. Transplant. 6 (2001) 34-39
77. Scherer R.U., Giebler R.M., Schmidt U., Paar D., and Kox W.J. The influence of C1-esterase inhibitor substitution on coagulation and cardiorespiratory parameters in an endotoxin-induced rabbit model of hypercoagulability. Semin. Thrombosis Hemostasis 22 (1996) 357-366
78. Schmidt W., Stenzel K., Walther A., Gebhard M.M., Martin E., and Schmidt H. Influence of C1-esterase inhibitor on tissue oxygenation of jejunal mucosa during endotoxemia. Int. J. Surg. Investig. 1 (1999) 277-283
79. Schmidt W., Stenzel Z., Gebhard M.M., Martin E., and Schmidt H. C1-esterase inhibitor and its effects on endotoxin-induced leukocyte adherence and plasma extravasation in postcapillary venules. Surgery 125 (1999) 280-287
80. Schumann R.R., and Latz E. Lipopolysaccharide-binding protein. Chem. Immunol. 74 (2000) 42-60
81. Schumann R.R., Lamping N., and Hoess A. Interchangeable endotoxin-binding domains in proteins with opposite lipopolysaccharide-dependent activities. J. Immunol. 159 (1997) 5599-5605
82. Segal B.H., Kuhns D.B., Ding L., Gallin J.I., and Holland S.M. Thioglycollate peritonitis in mice lacking C5, 5-lipoxygenase, or p47(phox): complement, leukotrienes, and reactive oxidants in acute inflammation. J. Leukoc. Biol. 71 (2002) 410-416
83. Sim R.B., Reboul A., Arlaud G.J., Villiers C.L., and Colomb M.G. Interaction of 125I-labelled complement components C1r and C1s with protease inhibitors in plasma. FEBS Lett. 97 (1979) 111-115
84. Stelter F., Bernheiden M., Menzel R., Jack R.S., Witt S., Fan X., Pfister M., and Schutt C. Mutation of amino acids 39-44 of human CD14 abrogates binding of lipopolysaccharide and Escherichia coli. Eur. J. Biochem. 243 (1997) 100-109
85. Stelter F., Loppnow H., Menzel R., Grunwald U., Bernheiden M., Jack R.S., Ulmer A.J., and Schutt C. Differential impact of substitution of amino acids 9-13 and 91-101 of human CD14 on soluble CD14-dependent activation of cells by lipopolysaccharide. J. Immunol. 163 (1999) 6035-6044
86. Strachan A.J., Woodruff T.M., Haaima G., Fairlie D.P., and Taylor S.M. A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats. J. Immunol. 164 (2000) 6560-6565
87. Strecker G., Ollier-Hartmann M.P., van Halbeek H., Vliegenthart J.F., Montreuil J., and Hartmann L. Primary structure of the glycan chains of normal C1 esterase inhibitor (C1-INH) after NMR analysis at 400 MHz. C. R. Acad. Sci. III 301 (1985) 571-576
88. Tassani P., Kunkel R., Richter J.A., Oechsler H., Lorenz H.P., Braun S.L., Eising G.P., Haas F., Paek S.U., Bauernschmitt R., Jochum M., and Lange R. Effect of C1-esterase-inhibitor on capillary leak and inflammatory response syndrome during arterial switch operations in neonates. J. Cardiothorac. Vasc. Anesth. 15 (2001) 469-473
89. Tietz N.W. Tietz Clinical Guide to Laboratory Tests (1995), W.B. Saunders, Philadelphia
90. Vestweber D., and Blanks J.E. Mechanisms that regulate the function of the selectins and their ligands. Physiol. Rev. 79 (1999) 181-213
91. Viriyakosol S., and Kirkland T.N. A region of human CD14 required for lipopolysaccharide binding. J. Biol. Chem. 270 (1995) 361-368
92. Viriyakosol S., Mathison J.C., Tobias P.S., and Kirkland T.N. Structure-function analysis of CD14 as a soluble receptor for lipopolysaccharide. J. Biol. Chem. 275 (2000) 3144-3149
93. Visintin A., Latz E., Monks B.G., Espevik T., and Golenbock D.T. Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to toll-like receptor-4 aggregation and signal transduction. J. Biol. Chem. 278 (2003) 48313-48320
94. Ziccardi R.J. Activation of the early components of the classical complement pathway under physiological conditions. J. Immunol. 126 (1981) 1768-1773